Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shin Nippon Biomedical Laboratories, Ltd. ( (JP:2395) ) has shared an update.
The company announced corrections to its consolidated financial results for the fiscal year ended March 31, 2025, due to discovered errors. These corrections impact the reported segment information, including net sales, segment assets, and other financial metrics, which may influence stakeholders’ understanding of the company’s financial health and operational performance.
The most recent analyst rating on (JP:2395) stock is a Hold with a Yen1460.00 price target. To see the full list of analyst forecasts on Shin Nippon Biomedical Laboratories, Ltd. stock, see the JP:2395 Stock Forecast page.
More about Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd. operates in the biomedical industry, focusing on contract research organization (CRO) services, translational research (TR), and Medipolis business, with an additional focus on property management in the US.
Average Trading Volume: 414,430
Technical Sentiment Signal: Sell
Current Market Cap: Yen56.66B
For detailed information about 2395 stock, go to TipRanks’ Stock Analysis page.